Cutting-edge cancer treatments – particularly in the field of immuno-oncology (IO) – are delivering a lifeline to patients. But as new therapies become available, even the best-resourced healthcare systems need to take decisions about how to provide access. The challenge is particularly acute in developing economies.

Throughout this series, MSD explores the reality of delivering better cancer treatment in emerging markets. In many cases, private health insurers are already making an impact through the development of new funding models.

So what are the lessons from innovative insurance programmes around the world that are increasing access to IO therapies – and what barriers are still stopping countries from expanding uptake?